People with a genetic predisposition to Parkinson’s disease are more likely to have early-onset symptoms, but lifestyle factors such as coffee consumption and tobacco and aspirin use may exert a more significant impact on that risk than common genetic risks, research findings suggest. While still exploratory, “our findings underline…
Mission Therapeutics has received $5.2 million from The Michael J. Fox Foundation (MJFF) and Parkinson’s UK to start clinical testing MTX325, its experimental and neuron-protective oral therapy, in people in the early stages of Parkinson’s disease. “This significant grant, from two of the world’s leading Parkinson’s disease…
Clumps of RNA-binding proteins have been discovered in the nucleus of nerve cells derived from people with Parkinson’s disease, according to a new study. Generated by a “self-propagating” cycle, these clumps were different and separate from those made from the protein alpha-synuclein, a well-known feature of Parkinson’s. A second…
Six months of once-daily buntanetap halted cognitive decline among people in the early stages of Parkinson’s disease, and improved cognition in those with mild dementia. That’s according to new data from a Phase 3 trial (NCT05357989), which showed that the therapy candidate, developed by Annovis Bio,…
Two proteins, Aplp1 and Lag3, pair to allow toxic aggregates of alpha-synuclein — a hallmark of Parkinson’s disease — into nerve cells and help it spread across the brain, according to a study in mice. “Now that we know how Aplp1 and Lag3 interact, we have a new way…
BrainTale’s noninvasive imaging analysis software, BrainTale-care, may be able to distinguish Parkinson’s disease from atypical parkinsonism. That’s according to data from an advanced MRI technique, called diffusion tensor imaging, that measures the diffusion of water molecules in the brain’s white matter. White matter contains nerve fibers…
People with Parkinson’s disease who don’t always take Nourianz (istradefylline) as prescribed are more likely to have fewer prescriptions for other approved medications and to have anxiety, mood changes, or cognitive problems, a study finds. Understanding how well patients follow the instructions for taking Nourianz, such as how…
An imaging agent for positron emission tomography (PET) scans allowed researchers to visualize, for the first time, abnormal alpha-synuclein protein clumps in the brains of living patients with Parkinson’s disease, a study showed. By detecting a hallmark feature of Parkinson’s found in relatively lower abundance in the brain compared…
Scientists at the Imperial College London in England have been awarded nearly £100,000, or about $125,000, by Parkinson’s UK to identify new therapeutic targets for Parkinson’s disease. The grant was awarded to Michael Johnson, PhD, and his team, and will fund efforts to harness the power of computers…
Once-daily treatment with Gain Therapeutics‘ GT-02287 rescued motor function and cognitive performance in a mouse model of Parkinson’s disease associated with mutations in the GBA1 gene. “These data further confirm our conviction that GT-02287 can slow or stop progression of Parkinson’s disease and given the cognitive decline observed…
Get regular updates to your inbox.
